Piscitelli Dominic sold $189K of ORIC
Piscitelli Dominic (Chief Financial Officer) sold 14,000 shares of Oric Pharmaceuticals, Inc. (ORIC) at $13.53 ($0.19M total) on 2026-10-20 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Insider sales can influence sentiment, but 10b5-1 pre-arranged plans generally reduce the informational content versus discretionary selling.
Market read
Traders may note the insider sale for sentiment monitoring, but the filing does not introduce new fundamentals or catalysts.
What to watch
The article provides no context on total insider holdings, whether sales are part of a larger scheduled pattern, or whether the sale was driven by taxes or diversification needs.
Background
The article is a SEC Form 4 insider transaction disclosure for Oric Pharmaceuticals, Inc.
Ticker impact
Oric Pharmaceuticals CFO Dominic Piscitelli sold 14,000 shares in an open-market transaction under a pre-arranged 10b5-1 plan on Oct. 20.
Likely limited near-term impact, with any price reaction more dependent on broader market sentiment than on this Form 4.
The filing is a Form 4 insider sale (code S) executed under a pre-arranged 10b5-1 plan, with no accompanying company-specific operational or guidance change disclosed in the text.
Market effects
Minimal, as this is an individual insider transaction with no disclosed sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as a mild negative signal about near-term outlook.
Key entities
- issuerOric Pharmaceuticals, Inc.
Company whose CFO Dominic Piscitelli executed an open-market sale under a pre-arranged 10b5-1 plan.
- insiderDominic Piscitelli
Chief Financial Officer who sold 14,000 shares at $13.5279 per share.

